Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing Nasdaq Delisting Notification On August 4, 2026 Lexaria Bioscience Corp. (the “Company”) received a notification (the “Notification”) from the Nasdaq Capital Market (“Nasdaq”) that, due to its failure to regain compliance with Nasdaq Listing Rule 5550(a)(2), being the requirement to maintain…
Filed Aug 10, 2026Accepted Aug 10, 2026, 5:00 PM EDTCIK 1348362Accession 0001640334-26-001302
Lexaria is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECHTM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 3.01Item 3.01 - Notice of Delisting
Item 3.01 Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing
Nasdaq Delisting Notification
On August 4, 2026 Lexaria Bioscience Corp. (the “Company”) received a notification (the “Notification”) from the Nasdaq Capital Market (“Nasdaq”) that, due to its failure to regain compliance with Nasdaq Listing Rule 5550(a)(2), being the requirement to maintain a $1.00 minimum bid price, (the “Bid Price Requirement”) within the 180 day compliance period provided under Nasdaq Listing Rule 5810(c)(3)(A), it would be delisted from the Nasdaq, subject to any request for a hearing to appeal such determination, which hearing request would stay the suspension of the Company’s shares from being delisted.
In anticipation of the Notification, the Company completed a reverse stock split on August 3, 2026 (as announced on July 30, 2026) and, since that time, the Company’s shares of common stock have been trading on Nasdaq under CUSIP number 52886N604 with a minimum bid price that is currently above the Bid Price Requirement. The Company has also filed its request for a hearing and paid the required fee in order to suspend the delisting of the Company’s shares from Nasdaq and to allow for the additional trading days necessary to regain the Bid Price Requirement. As of the date and time of this filing, the Company expects to regain compliance with the Nasdaq rules and requirements prior to any potential hearing date and expects its shares will remain trading on Nasdaq without interruption.